06-29-

Attorney's Docket No.: 17118-056002 / 2835E

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gevas et al.

Art Unit : 1642

Serial No.:

10/762,226

Examiner: Susan Ungar, Ph.D.

Filed

: January 20, 2004

Cust. No. : 20985 Conf. No.: 2197

Title

: IMMUNOLOGICAL METHODS FOR THE TREATMENT OF

GASTROINTESTINAL CANCER

# Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

# **TRANSMITTAL**

#### Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (5 pages), copies of two U.S. Office Actions, copies of two European Examination Reports, cited non U.S. patent documents listed on the form PTO-1449, and a return postcard for filing in connection with the above-captioned application. Because this Supplemental Information Disclosure Statement is filed with a Request for Continued Examination and prior to receipt of a first Office Action on the merits for the above-captioned application, a fee for filing this statement should not be due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No, 06-1050, as stated below:

 $\bowtie$ 

The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman Reg. No. 33,779

Attorney's Docket No.: 17118-056002 / 2835B

Address all correspondence to:

Stephanie Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130 Telephone: (858) 678-4777 Facsimile: (202) 626-7796

email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 965983373 US Date of Deposit June 27, 2007

Date of Deposit June 27, 2007 I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

Attorney's Docket No.: 17118-056002 / 2835B



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gevas et al. Art Unit: 1642

Serial No.: 10/762,226 Examiner: Susan Ungar, Ph.D.

Filed : January 20, 2004 Cust. No. : 20985

Conf. No.: 2197

Title : IMMUNOLOGICAL METHODS FOR THE TREATMENT OF

**GASTROINTESTINAL CANCER** 

## Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

This Supplemental Information Disclosure Statement is filed with a Request for Continued Examination of the above-captioned application and prior to receipt of an Office Action. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (5 pages) and copies of the cited non U.S. Patent documents are provided herewith in connection with the above-captioned application.

The documents cited on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

In accordance with the requirements of 37 C.F.R. §1.98, provided herewith and submitted for consideration by the Examiner is a copy of a U.S. Office Action (Document I), issued June 24, 1998, in connection with U.S. Patent Application No. 08/798,423 (Attorney Docket No. 17118-056001/2835). Also provided herewith is a copy of a European

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 965983373 US Date of Deposit June 27, 2007

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR \$1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VAL2333-1450.

Stephanie Se dman

Applicant: Gevas et al.

Serial No.: 10/762,226

Attorney's Docket No.: 17118-056002 / 2835B

Supplemental Information Disclosure Statement

Filed : January 20, 2004

Examination Report (Document II), issued September 17, 2003, in connection with European Patent Application No. 97905858.3 (Attorney Docket No. 17118-056EP1/2835EP), which is a national stage filing of International Patent Application No. PCT/US97/02029, which claims priority to U.S. Provisional Application Serial No. 60/011,411. The instant application is a continuation of U.S. Patent Application No. 08/798,423, which claims priority to U.S. Provisional Application Serial No. 60/011,411.

Also provided herewith and submitted for consideration by the Examiner is a copy of a U.S. Office Action (Document III), issued August 9, 2006, in connection with U.S. Patent Application No. 08/462158 (Attorney Docket No. 17118-054US3/2833CUS). In the Office Action, Examiner cited five documents: 1) US 4,526,716; 2) Bowie et al., "Deciphering the message in protein sequences: Tolerance to amino acid substitutions" Science 247:1306-1310 (1990); 3) Houghton et al., "Relative importance of position and individual amino acid residues in peptide antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic shift" Vaccine 86:21-25 (1986); 4) Iwanaga et al., "Immunocytochemical localization of the different gastrin forms in the pyloric antrum" Biomed. Res. 1:316-320 (1980); and 5) Siemann, "Satisfactory and unsatisfactory tumor models: Factors influencing the selection of a tumor model for experimental evaluation", Rodent Tumor Models in Experimental Cancer Therapy (Ed. Kallman) Pergamon Press, NY: 12-15 (1987). Also provided herewith is a copy of a European Examination Report (Document IV), issued November 18, 2003, in connection with European Patent Application No. 99921972.8 (Attorney Docket No. 17118-061EP1/2840EP). In the European Examination Report. Examiner cited 4 documents: D1) EP 0755683, D2) Ajani et al., "Phase I and II Studies of the Combination of Recombinant Human Interferon- and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma" J. Biol. Response Mod. 8(2):140-146 (1989); D3) Watson et al., "Anti-gastrin antibodies raised by gastrimmune inhibit growth of colorectaltumor AP5" Int. J. Cancer, 61(2):233-240 (1995); and D4) EP 0380230.

The table below lists Documents I-IV and includes a column that provides a space next to the document to be considered, for the Examiner's initials.

Examiner Initial	Document No.	Document
	I	Copy of Office Action, issued June 24, 1998, in connection with U.S. Patent Application No. 08/798,423

Applicant: Gevas *et al.*Serial No.: 10/762,226

Attorney's Docket No.: 17118-056002 / 2835B

Supplemental Information Disclosure Statement

Filed : January 20, 2004

Examiner Initial	Document No.	Document
	II	Copy of Examination Report, issued September 17, 2003, in connection with European Patent Application No. 97905858.3
	III	Copy of Office Action, issued August 9, 2006, in connection with U.S. Patent Application No. 08/462158
	IV	Copy of Examination Report, issued November 18, 2003, in connection with European Patent Application No. 99921972.8

Applicant also makes known to the Examiner the following U.S. and international applications, which are commonly owned and/or have one or more inventors in common:

Serial No.	Filing Date	Docket No.
09/700,402	12/04/01	17118-061US1/ 2840US
11/360,378	02/22/06	17118-062002/ 2841B
11/499,261	08/03/06	17118-064003/ 2843C
11/808,889	05/07/07	17118-064004/ 2843D
11/659,937	02/09/07	17118-066US1/ 2845US
11/663,126	03/16/07	17118-067US1/ 2846US
11/036,690	01/14/05	17118-073003/ 2849C
11/489,775	07/20/06	17118-073004/ 2849D
11/492,695	07/25/06	17118-073005/ 2849E

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the documents or information, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97 (g) and (h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56 (b) exists.

Applicant: Gevas *et al.* Serial No.: 10/762,226

Filed: January 20, 2004

Attorney's Docket No.: 17118-056002 / 2835B Supplemental Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing documents and make them of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie Seigman Reg. No. 33,779

Attorney's Docket No.: 17118-056002 / 2835B

Address all correspondence to:

Stephanie Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130 Telephone: (858) 678-4777

Facsimile: (202) 626-7796 email: seidman@fr.com

SLS/jtt

(Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 17118-056002/2835B

Application No. 10/762,226

Applicant Gevas et al.

Filing Date

Group Art Unit 1642

(37 CFR §1.98(b))

January 20, 2004

			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2005/0169979	08/04/05	Michaeli et al.	424	184.100	01/14/05
	AB	2007/0065454	03/22/07	Michaeli et al.	424	184.1	07/20/06
	AC	2007/0082043	04/12/07	Michaeli et al.	424	184.1	07/25/06
,	AD	3,931,141	01/06/76	Wissmann	530	329	11/15/73
	AE	4,302,386	11/24/81	Stevens	260	112.5	04/15/85
	AF	4,565,805	1/21/86	Smirnov	514	17	11/20/84
	AG	4,794,103	12/27/88	Bertolini	514	012	01/02/87
	AH	5,843,446	12/01/98	· Ladd et al.	424	184.1	06/07/95
	AI	6,815,414	11/09/04	Chowers et al.	514	008	12/15/00

	Foreig	n Patent Do	cuments or F	ublished Foreign	Patent A	pplication	าร	
Examiner	Desig.	Document	Publication	Country or			Trans	lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AJ	01/34192	05/17/01	PCT				
	AK	06/008649	01/26/06	PCT				
	AL	06/016275	02/16/06	PCT				
	AM	06/032980	03/30/06	PCT				
	AN	95/21380	08/10/95	PCT				

	Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner	Desig.						
Initial	l ID	Document					
	AO	AO Abrahm et al., "Development and evaluation of a high affinity species and region specific monoclonal antibody to human gastrin," Gastroenterology, 86(5(2)):1012, (1984).					
	AP	Beacham et al., "Human Gastrin: Isolation, Structure and Synthesis: Synthesis of Human Gastrin I", Nature 209(5023):585-586, (1966).					
	AQ	Bentley et al., "Human Gastrin: Isolation, Structure and Synthesis: Structures of Human Gastrins I and II" Nature 209(5023):583-585, (1966).					
	AR	Bowie et al., "Deciphering the message in protein sequences: Tolerance to amino acid substitutions," Science, 247:1306-1310, (1990).					
	AS	Bystryn, J., "Tumor vaccines," Cancer and Metastasis Reviews, 9:81-91, (1990).					
	AT	Caplin et al., "Serum gastrin levels and identification of CCK-B-gastrin receptor following partial hepatectomy for liver tumours in man," Gastroenterology, 110(4 suppl.) A1162, (1996).					

Examiner Signatui	e
-------------------	---

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226		
		d Publications for Applicant's n Disclosure Statement	Applicant Gevas et al.			
			Filing Date	Group Art Unit		
(37 CFR §1.98			January 20, 2004	1642		
		ocuments (include Author, 1	<u> Fitle, Date, and Place o</u>	f Publication)		
Examiner Initial	Desig. ID		Document			
	AU	Caplin et al., "Expression and process fibrolamellar carcinoma and cholangie (Abstract # L0083) (April 15, 1998).	ocarcinoma," Gastroenterology	114(Supplement 1): A1219		
	AV	Caplin et al., "Expression and process Gastroenterology 114(Supplement 1):	A445 (Abstract # G1809) (Apr.	il 15, 1998).		
	AW	Choudhury et al., "N-Terminal sequer immunochemical studies," A76 Hopp	e-Seyler's Z. Physiol. Chem., 36	1:1719-1733, (1980).		
	AX	Del Valle et al., "Progastrin and its gly human gastrointestinal tissues," Gastr	oenterology, 92:1908-1912, (19	87).		
	AY	Dickinson et al., "Gastrin-amidating e 266:334-338, (1991).				
	AZ	Dockray et al., "Heptadecapeptide gas Gastroenterology, 71(6):971-977, (19	76).	-		
	BA	Dockray et al., "Immunochemical studies on big gastrin using NH2-terminal specific antiserums," Chemical Abstracts, 94:506-507, (1981) [Abstract #94:119200w].				
	ВВ	Dockray et al., "Immunochemical studies on big gastrin using NH2-terminal specific antisera", Regulatory Peptides, 1:169-186, (1980).				
	ВС	Gregory et al., "Isolation of two gastrins from human antral mucosa," Nature, 209(5023):583, (1966).				
	BD	Halter et al., "Evaluation of a monoclonal anti-gastrin antibody as a tool for immunoneutralization gastrin during omeprazole treatment in the rat," Gastroenterology, 96(5) part 2:A194, (1989).				
	BE	Houghton et al., "Relative importance of position and individual amino acid residues in peptic antigen-antibody interactions: Implications in the mechanism of antigenic drift and antigenic Vaccine, 86:21-25, (1986).				
	BF	Hughes et al., "Therapy with gastrin a Diseases, 21:201-204, (1976).	ntibody in the zollinger-ellison s	syndrome," Digestive		
	BG	Iwanaga et al., "Immunocytochemical antrum," Biomed. Res., 1:316-320, (19		trin forms in the pyloric		
	BH Iwase et al., "Regulation of growth of human gastric cancer by gastrin and glycine-extend gastrin," Gastroenterology, 113:782-790, (1997).					
	ВІ	Jaffe et al., "Inhibition of endogenous terminal tetrapeptide of gastrin," Surgi		ith antibodies to the C-		
	BJ	Jaffe et al., "Inhibition of gastrin activ Surgery, 65(4):633-639, (1969).	ity with antibodies to C-termina	l tetrapeptide of gastrin,"		
	ВК	Joshi et al., "Gastrin and colon cancer (1996).		,		
	BL	Justin, T. and R. Steele et al., "Gastric a gastrin immunogren, Gastrimmune, (1995).	in an in vivo pig model," Gastro	penterology, 108(4):A125,		
	ВМ	Koh et al., "Glycine-extended gastrin g Gastroenterology, 110(4):1089, (1996	).			
BN Kohler et al., "Continuous cultures of fused cells secreting antibody of pature, 256:495-497, (1975).			f predefined specificity,"			

Examiner Signature	Date Considered					
EXAMINER: Initial if citation considered, whether or not citation is in co	nformance with MPEP 609; Draw line through citation if not in					
conformance and not considered. Include copy of this form with next communication to applicant.						

Substitute Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226			
		d Publications for Applicant's n Disclosure Statement	Applicant Gevas et al.			
			Filing Date	Group Art Unit		
(37 CFR §1.98			January 20, 2004	1642		
		ocuments (include Author, 1	litie, Date, and Place o	r Publication)		
Examiner Initial	Desig. ID		Document			
· · · · · · · · · · · · · · · · · · ·	ВО	Kothary et al., "Identification of gastr Peptides 17:71-84, (1987).				
	BP	Kovacs et al., "Gastrin partially media 17(4):583-587, (1996).				
	BQ	Kusyk et al., "Stimulation of growth of 251:G597-G601, (1986).		· ,		
	BR	Lamers et al., "Role of gastrin and cho Cancer Clin. Oncol., 24(2):267-273, (		strointestinal tract," Eur. J.		
	BS	Lamote et al., "Stimulating effect of p induced colon cancer in rats," Regulat		eration kinetics in chemically		
<u>-</u>	ВТ	Larsson et al. "Characterization of ant Cytochem., 25:1317-1321, (1977).		cific antisera," J. Histochem.		
	BU	Makishima et al., "Active immunization against gastrin-17 with an N-terminal derived immunoger inhibits gastric and duodenal lesions in rats," Gastroenterology, 106(4/2):A824, (1994) [Abstract].				
	BV	Makishima et al., "Inhibition of Gastrin-17 Stimulated acid secretion through active immunization in rats," FASEB J. 8:A92, Abs. 535, (1994).				
	BW	McGregor et al., "Trophic effects of gastrin on colorectal neoplasms in the rat", Ann. Surg., 195(2):219-223, (1982).				
	BX	McWilliams et al., "Coexpression of Gastrin and Gastrin Receptors (CCK-B and CCK-B) in gastrointestinal tumour cell lines," Gut, 42:795-798, (1998).				
	BY	Mu et al., "Monoclonal antibody to the gastrin receptor on parietal cells recognizes a 78-kDa protein," Proc. Natl. Acad. Sci., 84:2698-2702, (1987).				
	BZ	Negre et al., "Autocrine stimulation of extended gastrin," Int. J. Cancer, 66(5	f AR4-2J rat pancreatic tumour of	cell growth by glycine-		
	CA					
	СВ	Ohkura et al., "Gastrin-enhanced tumo nude mice," Jpn. J. Clin. Oncol., 10(2)	or growth of a xenotransplantable	e human gastric carcinoma in		
	CC	Ohning et al., "Gastrin mediates the ga Journal of Physiology, 271(3(1)):G47	astric mucosal proliferative respons	onse to feeding," American		
	CD	Okada et al., "Evaluation of cholecystogene expressions in gastrin cancer," C	okinin, gastrin, CCK-A receptor			
	CE	Palnaes et al., "Metabolism and influence of glycine-extended gastrin on gastric acid secretion is man," Digestion, 57:22-29, (1996).				
	CF	Power et al., "A novel gastrin-process 109(9):113, (1988) [Abstract #109:67:		um," Chemical Abstracts,		
	CG	Rahier et al., "Biosynthesis of Gastrin electron microscopic-immunogold me	Localization of the recursor and			
	СН	Rehfeld et al., "Gastrin in human bron	chogenic carcinomas: constant e			
	CI	processing of progastrin," Cancer Res., 49:2840-2843, (1989).  Romani et al. "Gastrin receptor antagonist CI-988 inhibits growth of human colon cancer in vivo a in vitro," AZN J. Surgery, 66:235-237, (1996).				

Examiner Signature	Date Considered						
	•						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in							
	conformance and not considered. Include copy of this form with next communication to applicant.						

Substitute Form PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office			Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226		
		d Publications for Applicant's n Disclosure Statement	Applicant Gevas et al.			
			Filing Date	Group Art Unit		
(37 CFR §1.98	B(b))		January 20, 2004	1642		
(	Other D	ocuments (include Author, <sup>-</sup>	Title, Date, and Place o	f Publication)		
Examiner	Desig.					
Initial	ID		Document			
	CJ	Seva et al., "Characterization of the gl Gastroenterology, A1005, (1995).		•		
	CK	Siemann, "Satisfactory and unsatisfactumor model for experimental evaluat (Ed. Kallman) Pergamon Press, NY:	tion", Rodent Tumor Models in L			
	CL	Singh et al., "Hormones in colon cano	·			
	СМ	Singh et al., "Incomplete processing of noncarboxyamidated gastrins," Journal	al of the American Physiological	Society, G459-G468, (1994).		
	CN	Singh et al., "Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors," J. Biol. Chem., 270:8429-8435, (1995).				
	СО	Singh et al., "Role of gastrin and gastrin receptors on the growth of a transplantable mouse colon carcinoma (MC-26) in BALB/c Mice," Cancer Res., 46:1612-1616, (1986).				
	СР	Smith et al. "Gastrin regulates the growth of human pancreatic cancer in a tonic and autocrine fashion," Amer. J. Physiol., 270(5):R1078-R1084, (1996).				
	CQ	Smith et al. "Identification of gastrin as a growth peptide in human pancreatic cancer," Amer. J. Physiol., 268:R135-R141, (1995).				
	CR	Smith et al., "Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer," Gastroenterology, 95(6):1541-1548 (1988).				
	CS	Sobhani et al., "Immunohistochemical characterization of gastrinomas with antibodies specific to different fragments of progastrin," Gastroenterol. Clin. Biol., 13:865-872, (1989).				
	СТ	Stepan et al., "Glycine-extended gastr Mol. Med., 5(3):147-159, (1999).				
	CU		rin in cancer cells expressing gastrin/CCK-B receptor," Cell and 7).			
	CV	Varro et al., "Pathways of processing 95:1642-1649, (1995).		tral mucosa," J. Clin. Invest.,		
	CW	Watson et al., "A hepatic invasive human colorectal xenograft model," Eur. J. Cancer, 29(12):1740-1745, (1993).				
	CX	Watson et al., "Detection of gastrin receptors on gastrointestinal tumors using the anti-gastrin receptor monoclonal antibody, 2CL," Gut, 4:F271, (1993).				
	CY	Watson et al., "Expression of gastrin-CCKB receptor isoforms in gastrointestinal tumor cells," Into Cancer, 77(4):572-577, (1998).				
	CZ	Watson et al., "Gastrin antagonists in 604, (1993).		<b>C</b> ()		
	DA	Watson et al., "The effect of the E2 pr sms201995, on the growth of a human	ostaglandin enprostil, and the son gastric cell line, MKN45G," In	matostatin analogue t. J. Cancer, 45:90-94, (1990).		
	DB	Watson et al., "Gastrin: growth promo Cancer, 59:554-558, (1989).				
	DC	Watson, S.A., et al., "Gastrin: growth enhancing effects on human gastric and colonic tumour cel British Journal of Surgery, 75(4):342-345, (1988)				

Examiner Signature	Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in			
conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17118-056002/2835B	Application No. 10/762,226			
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Gevas et al.				
(37 CFR §1.98(b))			Filing Date January 20, 2004	Group Art Unit 1642		
Other Documents (include Author, Title, Date, and Place of Publication)						
Examiner Initial	Desig. ID	Document				
	DD	Weinstock et al., "Binding of gastrin(17) to human gastric carcinoma cell lines" Cancer Res., 48(4):932-937, (1988).				
	DE	Wendlberger et al., "The syntheses of human big gastrin I and its 32-leucine analog", Chemical Abstracts 92(21):722 [Abstract #92:198749s].				
	DF	Yamaguchi et al., "Amino-terminal immunoreactivity of big gastrin in plasma and tumors obtained from patients with Zollinger-Ellison Syndrome" Chem. Abstracts 100:373 (1984) [Abstract #100:154661m].				

Examiner Signature Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.